STERISHEALTHCARE Products
Mumbai 08042755542 info@sterispharma.com
918209542042
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products ATOVASTRIN CV 20
ATOVASTRIN CV 20 At
ATOVASTRIN CV 20 At
COD not available
CARDIOLOGYRANGE by Atorvastatin & Clopidogrel

ATOVASTRIN CV 20

INR 124 INR 178
You Save: INR 54 (30.34%)
Check On
Share with
Check On
Share this on :

Description

Product details

ATOVASTRIN CV 20 Atorvastatin & Clopidogrel ATOVA CV 20 combines Atorvastatin and Clopidogrel to reduce cholesterol and prevent blood clots. It's used in managing heart disease and stroke prevention. Consult your doctor for dosing. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order NOW

Keywords

  • Filter tags

Other Products

Related Products

CARDULES ISMN SR 60 delivers Isosorbide Mononitrate IP 60mg in a sustained-release tablet form, designed for long-term prevention of angina in patients with coronary artery disease. Produced by Steris Healthcare Pvt Ltd, this formulation ensures steady drug release over 12-24 hours, optimizing cardiovascular protection with once-daily dosing convenience. It supports heart health by enhancing blood flow without the peaks and troughs of immediate-release options.​ Product Overview CARDULES ISMN SR 60 contains Isosorbide Mononitrate IP 60mg per sustained-release tablet, a pure nitrate metabolite that bypasses first-pass liver metabolism for consistent bioavailability. The SR technology employs a polymer matrix to gradually liberate the active ingredient, maintaining therapeutic plasma levels throughout the day and minimizing tolerance development associated with frequent dosing. Available in strips of 10 tablets, it features a film-coated exterior for easy swallowing and gastro-resistant properties to protect against stomach acid degradation.​ This higher 60mg strength suits patients requiring intensified prophylaxis after initial titration from lower doses like 30mg or 40mg. It integrates seamlessly into comprehensive cardiac regimens alongside beta-blockers, statins, or aspirin, under cardiologist supervision. Quality manufacturing adheres to IP standards, ensuring purity above 99% with low impurity profiles for safety in chronic use.​ Key Uses CARDULES ISMN SR 60 primarily prevents chronic stable angina pectoris by dilating coronary arteries and reducing myocardial oxygen demand during exertion. Patients experience fewer episodes of chest tightness, pressure, or discomfort triggered by physical activity, stress, or cold exposure.​ It manages coronary artery disease (CAD) by improving collateral circulation and easing ischemia in narrowed vessels. Often prescribed post-angioplasty or alongside lifestyle modifications, it stabilizes symptoms for enhanced daily functioning.​ Additionally, it supports adjunctive therapy in congestive heart failure or post-myocardial infarction recovery, where vasodilation unloads the heart. Not for acute attacks—use sublingual nitroglycerin instead—but vital for long-term risk reduction.​ Major Benefits The sustained-release profile of CARDULES ISMN SR 60 provides 24-hour angina prevention with single morning dosing, improving adherence over multiple-daily regimens. This steady vasodilation lowers preload via venous pooling and afterload via arterial relaxation, cutting oxygen consumption by up to 20-30% during stress.​ Patients report increased exercise tolerance, with treadmill tests showing delayed onset of ST-segment depression. Enhanced myocardial perfusion boosts energy levels, enabling return to work, hobbies, or family activities without fear of sudden symptoms.​ Compared to shorter-acting nitrates, tolerance buildup is slower due to a nitrate-free interval built into once-daily use. Cost-effective at higher strengths, it reduces overall healthcare visits and hospitalization risks from unstable angina.​ Benefit Mechanism Clinical Advantage Angina Prevention Vasodilation reduces preload/afterload ​ Fewer episodes, better quality of life Exercise Capacity Improved coronary flow ​ Extended activity duration by 50%+ Dosing Simplicity SR once daily ​ 90% adherence rate vs. multiple doses Heart Protection Lowers ischemia risk. ​ Reduced MI recurrence Potential Side Effects Common effects include headache (orthostatic or throbbing), especially in the first week, resolving with hydration and dose acclimation—acetaminophen helps manage it. Dizziness, lightheadedness, or postural hypotension may occur; rise slowly from sitting.​ Gastrointestinal upset like nausea or flushing affects 5-10% initially. Avoid alcohol or PDE5 inhibitors (e.g., sildenafil) to prevent severe hypotension.​ Rarely, reflex tachycardia, rash, or methemoglobinemia arises; monitor liver enzymes in prolonged use. Contraindicated in severe anemia, glaucoma, or recent PDE5 intake—discontinue if allergic reactions appear.​ Dosage Guidelines Initiate at 30-40mg daily, titrating to 60mg once in the morning on an empty stomach for optimal absorption. Swallow whole; do not crush. A 10-12 hour nitrate-free window (nighttime) prevents tolerance.​ Adjust for renal/hepatic impairment; max 120mg/day. Store below 25°C. Regular ECG and BP checks ensure efficacy.​ Conclusion CARDULES ISMN SR 60 stands as a cornerstone in angina prophylaxis, empowering CAD patients with reliable, sustained vascular relief from Steris Healthcare. Consistent use alongside diet, exercise, and smoking cessation maximizes outcomes, but cardiologist oversight remains essential for safety
View Details
Isosorbide mononitrate IP 60mg Tablets

INR155

CARDULES ISMN SR 30 tablets provide sustained-release Isosorbide Mononitrate IP 30mg, a nitrate medication designed for long-term management of angina in patients with coronary artery disease. This formulation from Steris Healthcare Pvt Ltd ensures steady vasodilation to improve heart blood flow and reduce chest pain episodes. It supports daily activities by minimizing oxygen demand on the heart muscle.​ Product Overview CARDULES ISMN SR 30 contains Isosorbide Mononitrate IP 30mg in a sustained-release matrix, allowing once-daily dosing for consistent therapeutic levels over 12-24 hours. The tablet's extended-release technology prevents peak-trough fluctuations common in immediate-release forms, promoting better patient compliance. Each film-coated tablet delivers precise bioavailability, with the active metabolite nitric oxide activating guanylate cyclase to boost cyclic GMP, relaxing vascular smooth muscle primarily in veins.​ This mechanism reduces preload (venous return to the heart) and afterload (arterial resistance), easing cardiac workload without significantly affecting heart rate. Unlike short-acting nitrates for acute relief, CARDULES ISMN SR 30 targets prophylaxis in chronic stable angina, often prescribed alongside beta-blockers or calcium channel blockers. Available in strips of 10 tablets, it undergoes rigorous quality testing at Steris facilities to meet IP standards, ensuring purity and stability.​ Key Uses CARDULES ISMN SR 30 primarily prevents angina pectoris in coronary artery disease, where narrowed vessels limit oxygen supply during exertion. Patients experience fewer chest pain attacks during walking, climbing stairs, or stress.​ It manages chronic stable angina by enhancing myocardial perfusion, suitable for long-term therapy in adults over 18. Healthcare providers may use it adjunctively for coronary spasm or post-myocardial infarction prophylaxis to stabilize symptoms.​ In select cases, it aids heart failure management by offloading the heart, though not as monotherapy. Always initiate under cardiology supervision with dose titration to tolerance.​ Major Benefits The sustained-release profile offers 24-hour protection with single morning dosing, improving adherence and lifestyle quality for active patients. It boosts exercise tolerance by 20-30% in trials, allowing longer physical efforts without angina onset.​ By dilating vessels, it decreases ischemia risk, potentially lowering hospitalization rates for acute episodes. Compared to placebo, users report halved attack frequency within weeks, enhancing daily productivity and emotional well-being.​ Benefit Mechanism Patient Outcome Angina Prevention Vasodilation reduces preload/afterload ​ Fewer attacks, better exertion capacity Steady Relief SR formulation maintains levels ​ Once-daily convenience, no fluctuations Heart Protection Improves O2 delivery ​ Reduced ischemia, enhanced QoL Compliance Boost Simple regimen ​ Higher adherence vs multiple doses Additional perks include minimal impact on blood pressure in normotensives and compatibility with anti-anginals, making it versatile in combo therapy. Potential Side Effects Common effects include headache (dose-related, often transient in first week), dizziness, or flushing due to vasodilation—hydrate and rise slowly to manage. Gastrointestinal upset like nausea occurs in 5-10% initially.​ Orthostatic hypotension risks fainting, especially early; avoid alcohol or other vasodilators. Rare serious issues encompass severe hypotension, tachycardia, or methemoglobinemia with overdose—monitor blood pressure regularly.​ Allergic reactions (rash, itching) or vision changes warrant discontinuation. Contraindicated in hypotension, glaucoma, or recent PDE5 inhibitor use; caution in anemia or hypothyroidism.​ Dosage Guidelines Start with 30mg once daily upon waking, swallowed whole without crushing. Titrate to 60mg if tolerated after 3-7 days, max 120mg/day. Take on empty stomach for optimal absorption; avoid late dosing to prevent nocturnal headaches.​ Adjust for elderly or renal/hepatic impairment. Tolerance may develop—nitrate-free interval (evening) helps sustain efficacy. Store below 30°C.​ Conclusion CARDULES ISMN SR 30 empowers angina patients with reliable, once-daily prevention, restoring confidence in routine activities under Steris Healthcare's quality assurance. Its targeted vasodilation balances efficacy and tolerability for sustained heart health
View Details
Isosorbide Mononitrate IP 30mg Tablets

INR65

REBATERIS 100 contains Ribavirin IP 100mg in a hard gelatin capsule filled with white to off-white powder for optimal stability and bioavailability. Each pack typically includes 30 capsules, designed for oral administration with food to enhance absorption and reduce gastrointestinal upset. Ribavirin, a synthetic guanosine nucleoside analog, interferes with viral RNA polymerase and mRNA capping, halting hepatitis C virus (HCV) replication at multiple stages. This broad-spectrum antiviral also shows activity against respiratory syncytial virus (RSV) in select pediatric cases, though its primary indication remains HCV genotype management.​ The 100mg strength allows for weight-based dosing adjustments, making REBATERIS 100 suitable for adults and children over 3 years under specialist supervision. Unlike higher 200mg capsules, it supports finer dose reductions during therapy to manage side effects, ensuring better tolerability. Stored at room temperature away from moisture, it maintains potency for extended shelf life, aligning with pharmacopeial standards for purity and dissolution.​ Key Uses REBATERIS 100 treats chronic hepatitis C virus infection in combination therapies, particularly for patients ineligible for all-oral direct-acting antivirals. It boosts sustained virologic response rates when paired with pegylated interferon alfa, addressing genotypes 1 through 6 based on regional guidelines.​ In severe RSV lower respiratory tract infections, off-label use occurs in hospitalized infants, where aerosolized forms predominate, but oral REBATERIS 100 contributes to interferon combos for immunocompromised children. It curbs viral load, prevents liver fibrosis progression, and reduces cirrhosis risk, making it essential for long-term liver preservation.​ Additionally, emerging evidence supports its adjunct role in certain hemorrhagic fevers like Lassa virus, though availability limits widespread application. Always initiated by hepatologists, treatment durations span 24-48 weeks depending on genotype, viral load, and response milestones.​ Major Benefits REBATERIS 100 enhances viral clearance, achieving up to 50-80% sustained response rates in interferon combinations, significantly lowering hepatocellular carcinoma risk over five years. Patients experience normalized liver enzymes and fibrosis regression on biopsy follow-up.​ Its oral capsule form simplifies adherence compared to injectables, with twice-daily dosing fitting daily routines. The 100mg potency permits precise titration—e.g., 800-1400mg daily divided—for personalized therapy, minimizing excess exposure in lighter patients.​ Long-term, it preserves liver function, averting transplants and improving quality of life metrics like fatigue reduction and work productivity. Cost-effective for resource-limited settings, REBATERIS 100 bridges gaps until pan-genotypic regimens become accessible.​ Benefit Mechanism Clinical Impact Viral Suppression RNA polymerase inhibition ​ >50% SVR in combos ​ Liver Protection Fibrosis halt ​ Reduced cirrhosis by 30-40% Flexible Dosing 100mg increments ​ Better tolerability, adherence Broad Genotype Coverage Multi-genotype efficacy ​ Versatile for diverse patients Potential Side Effects Common side effects include hemolytic anemia, peaking at weeks 4-8, necessitating hemoglobin monitoring and dose cuts to 600mg daily if levels drop below 10g/dL. Fatigue, headache, and insomnia affect over 40% of users, often resolving post-therapy.​ Gastrointestinal issues like nausea, diarrhea, and anorexia occur in 20-30%, mitigated by food intake. Dermatologic reactions—rash, pruritus—or flu-like symptoms from interferon pairing demand vigilance. Teratogenicity risks are high; dual contraception is mandatory for 6 months post-treatment due to sperm/ovum mutagenicity.​ Serious risks encompass pulmonary infiltrates, cardiac ischemia in vulnerable patients, and thyroid dysfunction. Avoid in hemoglobinopathies, severe renal impairment (CrCl <50mL/min), or pregnancy. Regular blood counts and ophthalmologic exams guide safe continuation.​ Dosage Guidelines Dosing is weight-based: adults <75kg receive mg/day (10 capsules: 5 AM, 5 PM); ≥75kg get 1200 mg/day (12 capsules: 6 AM, 6 PM), swallowed whole with meals. Pediatrics (≥3 years): 15mg/kg/day divided BID, rounded to the nearest 100mg via REBATERIS 100 capsules.​ Reduce by 200-400mg for anemia or neutropenia; discontinue if unresolved. Duration: 48 weeks for genotype 1, 24 weeks for others, with viral load checks at week 12. Swallow intact; no crushing.​ Conclusion REBATERIS 100 empowers hepatitis C management with proven antiviral potency and dosing precision from Steris Healthcare. It transforms prognosis for countless patients, but demands specialist oversight amid monitoring needs
View Details
RIBAVIRIN CAPSULES IP 100mg

INR2900

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us